Table 2.
Outcomes following chemo (± immuno) therapy in patients with primary mediastinal large B-cell lymphoma in the recent literature
| Study (Reference) | Number of adult patients (n) | Type of study | Therapy given | PD on chemo (± immuno) therapy | Mediastinal RT given to % | Median follow up duration | EFS | OS |
|---|---|---|---|---|---|---|---|---|
| Xu et al. (4) |
40 39 |
Retrospective |
CHOP R-CHOP |
16.5% |
70% 82.1% |
61.0 m |
44.2% 76.7% (5-yrs PFS) |
48.3% 83.7% (5-yrs) |
| Dunleavy et al. (6) | 51 | Prospective | DA-R-EPOCH | 1.9% | 4% | 63.0 m | 93% | 97% |
| Giulino-Roth et al. (7) | 118 | Retrospective | DA-R-EPOCH | 1.7% | 14.9% | 22.6 m |
85.9% (3-yrs) |
95.4% (3-yrs) |
| Chan et al. (13) |
41 37 46 |
Retrospective |
R-CHOP R-CHOP + RT DA-R-EPOCH |
Not available |
0% 100% 6% |
45.0 m (overall) |
56.0% 90% 88.5% (5-yrs PFS) |
76.1% 93.9% 96.9% (5-yrs) |
| Malenda et al. (14) |
25 28 |
Retrospective |
CHOP DA-R-EPOCH |
4%3.7% |
76.0% 59.3% |
45.0 m 23.5 m |
87% 73.9% (1-yr PFS) |
100% 92% (1-yr) |
| Gogia et al. (15) | 12 | Retrospective | DA-R-EPOCH | 8.3% | 16.7% | 29.0 m |
75% (2-yrs) |
83% (2-yrs) |
| Present study | 37 | Retrospective | DA-R-EPOCH | 2.7% | 45.9% | 40.0 m |
78.4% (3-yrs) |
80.6% (3-yrs) |
PFS, progression-free survival; OS, overall survival; EFS, event-free survival; m, months; RT, radiotherapy